

AMENDMENTS TO THE CLAIMS

1-74 (Canceled)

75. (Currently amended) A method for detecting whether a subject is likely to have a colon neoplasia comprising:

- a) obtaining a biological sample from said subject;
- b) detecting in the biological sample one or more polypeptides selected from among: one or more secreted ColoUp1 polypeptides and one or more secreted ColoUp2 polypeptides selected from the group consisting of: a) a secreted polypeptide produced by the expression of a nucleic acid having the sequence of SEQ ID No: 5, and b) a secreted polypeptide having an amino acid sequence of SEQ ID No: 3, wherein the presence of said at least one polypeptide is indicative of colon neoplasia.

76. – 83. (Canceled)

84. (Original) The method of claim 75, wherein the biological sample is a blood sample or a fraction derived from blood.

85. (Original) The method of claim 84, wherein the biological sample is selected from among: whole blood, blood plasma, and blood serum.

86. (Original) The method of claim 75, wherein the biological sample is derived from the inner wall and/or lumen of the intestinal tract.

87. (Original) The method of claim 86, wherein the biological sample is a stool sample.

88. (Original) The method of claim 75, wherein the biological sample is a urine sample.

89. (Original) The method of claim 75, wherein the polypeptide is detected by an assay that employs an antibody.

90. (Original) The method of claim 89, where the assay is selected from among: an immunoprecipitation assay, a Western blot, a radioimmunoassays and an enzyme-linked immunosorbent assay (ELISA).

91. (Currently amended) The method of claim 89, wherein the assay comprises contacting the biological sample with an antibody that interacts with ~~a secreted ColoUp1 polypeptide or a~~ said secreted ColoUp2 polypeptide.
92. (Canceled)
93. (Original) The method of claim 89, wherein the antibody interacts with an epitope of the amino acid sequence of SEQ ID No: 3.
94. (Currently amended) The method of claim 89, wherein the antibody interacts with an epitope ~~of the amino acid sequence of SEQ ID No: 21~~ said polypeptide produced by the expression of the nucleic acid sequence set forth in SEQ ID NO: 5.
95. (Original) The method of claim 89, wherein the antibody is detectably labeled.
96. (Original) The method of claim 95, wherein the label is selected from the group consisting of an enzyme, a fluorescent substance, a chemiluminescent substance, a chromophore, a radioactive isotope and a complexing agent.
97. (Currently amended) The method of claim 75, further comprising determining the amount of ~~at least one secreted ColoUp1 polypeptide and/or~~ said at least one ColoUp2 polypeptide in the biological sample.
98. (Currently amended) The method of claim 75, wherein the amount of ~~at least one secreted ColoUp1 polypeptide and/or~~ said at least one secreted ColoUp2 polypeptide in the biological sample is compared to a predetermined standard.
99. (Currently amended) The method of claim 75, wherein the amount of ~~at least one secreted ColoUp1 polypeptide and/or~~ said at least one secreted ColoUp2 polypeptide in the biological sample is compared to the subject's historical baseline.
100. (Currently amended) The method of claim 75, wherein the presence of ~~at least one secreted ColoUp1 polypeptide and/or~~ said at least one secreted ColoUp2 polypeptide is indicative that the subject is likely to harbor a colon adenoma or a colon cancer.

101. (Currently amended) The method of claim 75, wherein the presence of ~~at least one secreted ColoUp1 polypeptide and/or~~ said at least one secreted ColoUp2 polypeptide aids in determining the therapeutic protocol to be administered to a subject having a colon neoplasia.
102. (Original) The method of claim 75, wherein the subject was not previously diagnosed with colon cancer.
103. (Currently amended) The method of claim 75, wherein the subject has previously received or is currently receiving a therapy for colon cancer, wherein the presence of ~~at least one secreted ColoUp1 polypeptide and/or~~ said at least one secreted ColoUp2 polypeptide indicates that the subject is likely to have a relapse or a persistent or progressive colon cancer.
104. (Original) The method of claim 75, wherein the colon neoplasia is a colon adenoma.
105. (Original) The method of claim 75, wherein the colon neoplasia is colon cancer.
106. (Original) The method of claim 75, wherein the colon neoplasia is metastatic colon cancer.
107. -122. (Canceled)
123. (New) The method of claim 75, wherein the polypeptide produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having the sequence of SEQ ID NO: 21.